Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.

Christensen SE, Weeke J, Orskov H, Møller N, Flyvbjerg A, Harris AG, Lund E, Jørgensen J

Clinical endocrinology1 Sept 1987Cited by 50 (Europe PMC)

PMID2892599DOI10.1111/j.1365-2265.1987.tb01156.xPepBankPUB-02892599

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanNon-randomized trialEfficacy outcome
In acromegaly, continuous octreotide infusion produced greater, more stable 24 h GH suppression than injections, reaching injection nadir levels.
In plain wordsIn acromegaly, continuous octreotide infusion suppressed growth hormone more strongly and steadily than daily injections.
Peptide
Octreotide
Outcome
Decrease24-hour GH suppression with infusion
Study
n = 10
Comparator
Three equal daily octreotide injections
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Source sentences
Summary
In contrast, continuous infusion resulted in greater and more stable 24 h suppression to the levels reached at the nadir between injections.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259902
02HumanNon-randomized trialEfficacy outcome
In acromegaly, octreotide pump treatment achieved mean 24 h GH below 5 ng/ml in four patients.
In plain wordsIn acromegaly, four patients reached average growth hormone below 5 ng/ml during octreotide pump treatment.
Peptide
Octreotide
Outcome
Not applicableMean GH below 5 ng/ml with pump
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Measurements
Patients with mean 24 h serum GH below 5 ng/ml
4 patients
continuous s.c. pump infusion
Source sentences
Summary
Suppression of mean 24 h serum GH below 5 ng/ml was achieved by pump treatment in four patients, while two patients had mean values between 5 ng/ml and 10 ng/ml.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259903
03HumanNon-randomized trialEfficacy outcome
In acromegaly, two patients had mean GH between 5 ng/ml and 10 ng/ml during octreotide pump treatment.
In plain wordsIn acromegaly, two patients had average growth hormone between 5 and 10 ng/ml during octreotide pump treatment.
Peptide
Octreotide
Outcome
Not applicableMean GH between 5 and 10 ng/ml with pump
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Measurements
Patients with mean 24 h serum GH between 5 and 10 ng/ml
2 patients
continuous s.c. pump infusion
Source sentences
Summary
Suppression of mean 24 h serum GH below 5 ng/ml was achieved by pump treatment in four patients, while two patients had mean values between 5 ng/ml and 10 ng/ml.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259904
04HumanNon-randomized trialEfficacy outcome
In acromegaly, carbohydrate tolerance was unaffected during continuous octreotide pump infusion.
In plain wordsIn acromegaly, octreotide pump treatment did not change carbohydrate tolerance compared with pretreatment.
Peptide
Octreotide
Outcome
No significant changeCarbohydrate tolerance with pump
Study
n = 10
Comparator
Pretreatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Source sentences
Summary
Carbohydrate tolerance was unaffected in either regimen, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259906
05HumanNon-randomized trialEfficacy outcome
In acromegaly, carbohydrate tolerance was unaffected during the octreotide injection regimen.
In plain wordsIn acromegaly, octreotide injections did not change carbohydrate tolerance compared with pretreatment.
Peptide
Octreotide
Outcome
No significant changeCarbohydrate tolerance with injections
Study
n = 10
Comparator
Pretreatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Source sentences
Summary
Carbohydrate tolerance was unaffected in either regimen, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259907
06HumanNon-randomized trialEfficacy outcome
In acromegaly, octreotide did not inhibit TSH release.
In plain wordsIn acromegaly, octreotide did not suppress TSH release.
Peptide
Octreotide
Outcome
No significant changeTSH release
Study
n = 10
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Source sentences
Summary
Interestingly, and in contrast to somatostatin, SMS 201-995 did not inhibit TSH release.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259908
07HumanNon-randomized trialSafety outcome
In acromegaly, no untoward effects were observed at the studied moderate octreotide dosage.
In plain wordsIn acromegaly, no unwanted effects were observed at the studied octreotide dosage.
Peptide
Octreotide
Outcome
Not applicableUntoward effects
Study
n = 10
Outcome group
Adverse events · Whole body
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Source sentences
Summary
No untoward effects were observed at the moderate dosage and blood clinical chemistry was unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259909
08HumanNon-randomized trialSafety outcome
In acromegaly, blood clinical chemistry remained unchanged during the studied octreotide regimens.
In plain wordsIn acromegaly, blood chemistry did not change during octreotide treatment compared with pretreatment.
Peptide
Octreotide
Outcome
No significant changeBlood clinical chemistry
Study
n = 10
Comparator
Pretreatment
Outcome group
Adverse events · Whole body
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Source sentences
Summary
No untoward effects were observed at the moderate dosage and blood clinical chemistry was unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259910
09HumanNon-randomized trialPharmacokinetics
In acromegaly, octreotide concentrations stayed fairly constant during pump infusion but fluctuated inversely with GH during injections.
In plain wordsIn acromegaly, blood octreotide levels stayed steadier with pump infusion than injections.
Peptide
Octreotide
Outcome
Not applicableDiurnal octreotide concentration pattern
Study
n = 10
Comparator
Octreotide injections
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Source sentences
Summary
Fairly constant diurnal serum SMS 201-995 values were obtained during pump infusion, while levels undulated inversely with serum GH during injection treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259911
10HumanNon-randomized trialEfficacy outcome
In acromegaly, reported somatostatin-C immunoreactivity fell from 496 +/- 129 to 385 +/- 100 ng/ml during octreotide pump treatment (P less than 0.003).
In plain wordsIn acromegaly, reported somatostatin-C immunoreactivity decreased during octreotide pump treatment compared with pretreatment.
Peptide
Octreotide
Outcome
DecreaseSomatostatin-C immunoreactivity with pump
Study
n = 10
Comparator
Pretreatment
Outcome group
Somatostatin immunoreactivity · Endocrine and hormones
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Measurements
Serum somatostatin-C immunoreactivity
496 ng/ml
before pump treatment, mean +/- SD 129
Serum somatostatin-C immunoreactivity
385 ng/ml
during pump treatment, mean +/- SD 100
P value
< 0.003
pump treatment versus before
Source sentences
Summary
Average diurnal serum somatostatin-C immunoreactivity (all patients) decreased from 496 +/- 129 (mean +/- SD) to 385 +/- 100 ng/ml (P less than 0.003) during pump treatment and did not decrease further during the following 3 d injection treatment (363 +/- 76 ng/ml).
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259912
11HumanNon-randomized trialEfficacy outcome
In acromegaly, somatostatin-C immunoreactivity did not decrease further during the subsequent 3 d of octreotide injections (363 +/- 76 ng/ml).
In plain wordsIn acromegaly, reported somatostatin-C immunoreactivity did not fall further with octreotide injections after pump treatment.
Peptide
Octreotide
Outcome
No significant changeSomatostatin-C immunoreactivity with injections
Study
n = 10
Comparator
Prior octreotide pump treatment
Outcome group
Somatostatin immunoreactivity · Endocrine and hormones
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Measurements
Serum somatostatin-C immunoreactivity
363 ng/ml
following 3 d injection treatment, mean +/- SD 76
Source sentences
Summary
Average diurnal serum somatostatin-C immunoreactivity (all patients) decreased from 496 +/- 129 (mean +/- SD) to 385 +/- 100 ng/ml (P less than 0.003) during pump treatment and did not decrease further during the following 3 d injection treatment (363 +/- 76 ng/ml).
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259913
12HumanNon-randomized trialEfficacy outcome
In eight acromegaly patients, octreotide injections suppressed GH for 3-6 h, followed by return to pretreatment values before the next injection.
In plain wordsIn eight acromegaly patients, octreotide injections suppressed growth hormone for 3-6 hours before levels returned to pretreatment values.
Peptide
Octreotide
Outcome
DecreaseGH suppression after injections
Study
n = 8
Comparator
Pretreatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
33 micrograms per injection · subcutaneous · 3 days per regimenAs given in this study (human).
Measurements
Duration of serum GH suppression
3 to 6 h
after 33 microgram subcutaneous injections, 8 patients
Source sentences
Summary
Subcutaneous injections (33 micrograms) induced impressive suppression of serum GH lasting 3-6 h in eight patients followed by escape to pretreatment values before the next injection.
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259901
13HumanNon-randomized trialEfficacy outcome
In four acromegaly patients, occasional or all GH levels exceeded 10 ng/ml during octreotide infusion, with 24 h averages of 12.4-102 ng/ml.
In plain wordsIn four acromegaly patients, growth hormone sometimes or always exceeded 10 ng/ml during octreotide pump treatment.
Peptide
Octreotide
Outcome
Not applicableResidual high GH with pump
Study
n = 4
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms/24 h · subcutaneous · 3 days per regimenAs given in this study (human).
Measurements
Patients with occasional or all GH levels above 10 ng/ml
4 patients
continuous s.c. pump infusion
24 h average serum GH
12.4 to 102 ng/ml
patients with levels above 10 ng/ml during pump infusion
Source sentences
Summary
In four patients occasional or all levels were above 10 ng/ml (24 h average 12.4-102 ng/ml)
1 context sentence(design, population, supporting numbers)
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259905
14HumanNon-randomized trialEfficacy outcome
In one acromegaly patient, tumor volume decreased from 8.2 to 4.1 cm3 across the experimental week of octreotide regimens.
In plain wordsIn one acromegaly patient, tumor volume decreased from 8.2 to 4.1 cm3 during the week of octreotide regimens.
Peptide
Octreotide
Outcome
DecreaseTumor volume in first patient
Study
n = 1
Comparator
Before experimental week
Outcome group
Tumor growth · Cancer
Studied dose
100 micrograms/24 h · subcutaneousAs given in this study (human).
Measurements
Extracellular tumour volume
8.2 cm3
first patient, before
Extracellular tumour volume
4.1 cm3
first patient, after
Source sentences
Summary
Two patients had extracellular tumours whose size decreased from 8.2 to 4.1 cm3 and from 12.6 to 10.5 cm3.
2 context sentences(design, population, supporting numbers)
Summary · context
Computer tomographic (CT) scans of the sellar region were performed in all patients before and after the experimental week.
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259914
15HumanNon-randomized trialEfficacy outcome
In one acromegaly patient, tumor volume decreased from 12.6 to 10.5 cm3 across the experimental week of octreotide regimens.
In plain wordsIn one acromegaly patient, tumor volume decreased from 12.6 to 10.5 cm3 during the week of octreotide regimens.
Peptide
Octreotide
Outcome
DecreaseTumor volume in second patient
Study
n = 1
Comparator
Before experimental week
Outcome group
Tumor growth · Cancer
Studied dose
100 micrograms/24 h · subcutaneousAs given in this study (human).
Measurements
Extracellular tumour volume
12.6 cm3
second patient, before
Extracellular tumour volume
10.5 cm3
second patient, after
Source sentences
Summary
Two patients had extracellular tumours whose size decreased from 8.2 to 4.1 cm3 and from 12.6 to 10.5 cm3.
2 context sentences(design, population, supporting numbers)
Summary · context
Computer tomographic (CT) scans of the sellar region were performed in all patients before and after the experimental week.
Summary · context
Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h.
Report a problemFND-0289259915

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.